Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 939-951

  Nagaria, Teddy S ^a,b   Williams, Julia L ^a,b   Leduc, Charles ^a,b   Squire, Jeremy A ^a,b   Greer, Peter A ^a,b   Sangrar, Waheed ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1, 3, 5 (10) TRIEN 17BETA YL) AMINO] HEXYL] 1H PYRROLE 2, 5 DIONE; 1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; AZD 5483; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FASCAPLYSIN; FLAVOPIRIDOL; LAPATINIB; PALBOCICLIB; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84881032733     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13804     Document Type: Article

References (56)

1. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, et al. (2007). Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40, 580-594.
2. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, and Slamon DJ (2004). Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96, 739-749.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart S. G, Udove J, Ullrich A, et al. (1989). Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244, 707-712.
4. Janne PA, Gray N, and Settleman J (2009). Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8, 709-723.
5. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P., Matthews N, Stewart A, Tarpey P, et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883-892.
6. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, and Hachitanda Y (2002). Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8, 3454-3460.
7. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M., Ben-Chetrit N, Sela M, et al. (2013). Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci USA 110, 1815-1820.
8. Roberts PJ and Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310.
9. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn S. C, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402.
10. Hindley A and Kolch W (2002). Extracellular signal regulated kinase (ERK)/ mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 115, 1575-1581.
11. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, and Lynch M (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7, 3129-3140.
12. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho S. C, Gomez P, Van Eyll B, Bermejo B, et al. (2012). Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30, 1484-1491.
13. Singh S, Johnson J, and Chellappan S (2010). Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim Biophys Acta 1799, 788-794.
14. Sherr CJ and McCormick F (2002). The RB and p53 pathways in cancer. Cancer Cell 2, 103-112.
15. Davis R and Chellappan S (2008). Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer. Drug News Perspect 21, 331-335.
16. Sutherland R and Musgrove E (2009). CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 11, 112.
17. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X., Vincent P, McHugh M, et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109.
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C., Desai AA, Rolland F, et al. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27, 3312-3318.
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A., Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
20. Senderowicz AM (1999). Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17, 313-320.
21. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R., Kelsen DP, and Schwartz GK (2007). Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 13, 5841-5846.
22. Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, et al. (2012). A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol 127, 55-62.
23. Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C., Walker M, Newcombe N, et al. (2009). AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther 8, 1856-1866.
24. Dickson MA and Schwartz GK (2009). Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16, 36-43.
25. Senderowicz AM (2002). The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7(suppl 3), 12-19.
26. Musgrove EA, Caldon CE, Barraclough J, Stone A, and Sutherland RL (2011). Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11, 558-572.
27. Chou TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
28. Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, and Mani S (2002). Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 1, 695-706.
29. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H., Tatsumi T, Kanto T, et al. (2012). Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 131, 548-557.
30. Motwani M, Rizzo C, Sirotnak F, She Y, and Schwartz G (2003). Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2, 549-555.
31. Collins T (2007). ImageJ for microscopy. Biotechniques 43, 25-30.
32. Albeck J, Mills G, and Brugge J (2013). Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell 49, 249-261.
33. Knudsen ES and Wang JY (1997). Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771-5783.
34. Nahta R, Iglehart JD, Kempkes B, and Schmidt EV (2002). Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 62, 2267-2271.
35. Mitchell C, Yacoub A, Hossein H, Martin A, Bareford M, Eulitt P, Yang C, Nephew K., and Dent P (2010). Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10, 903-917.
36. Senderowicz A, Headlee D, Stinson S, Lush R, Kalil N, Villalba L, Hill K, Steinberg S., Figg W, Tompkins A, et al. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16, 2986-2999.
37. Sparreboom A, van Tellingen O, Nooijen W, and Beijnen J (1996). Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56, 2112-2115.
38. Arguello F, Alexander M, Sterry J, Tudor G, Smith E, Kalavar N, Greene J, Koss W., Morgan C, Stinson S, et al. (1998). Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490.
39. Drees M, Dengler W, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville E., and Fiebig H (1997). Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3, 273-279.
40. Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, et al. (2009). Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 8, 1729-1736.
41. Booy E, Henson E, and Gibson S (2011). Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 30, 2367-2378.
42. Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, and Chellappan S. P (2004). Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 24, 9527-9541.
43. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, and Carter C (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851-11858.
44. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, and ZoliW(2009). Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220, 214-221.
45. Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, et al. (2010). Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 9, 2090-2101.
46. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, et al. (2012). Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 18, 263-272.
47. Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, Fabris L, Fiorotto R., and Strazzabosco M (2012). Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 56, 2363-2374.
48. Ma Y, Cress W, and Haura E (2003). Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2, 73-81.
49. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, and Senderowicz AM (1999). Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59, 5433-5437.
50. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M., Chen C, McNabola A, et al. (2007). Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59, 561-574.
51. Semrad T, Gandara D, and Lara P (2011). Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol 3, 95-100.
52. Nath N, Wang S, Betts V, Knudsen E, and Chellappan S (2003). Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclindependent kinases. Oncogene 22, 5986-5994.
53. Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, et al. (2013). Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res 19, 2745-2754.
54. Reis-Filho JS and Tutt AN (2008). Triple negative tumours: a critical review. Histopathology 52, 108-118.
55. Filmus J, Pollak MN, Cailleau R, and Buick RN (1985). MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128, 898-905.
56. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee E. H, Barcellos-Hoff MH, Petersen OW, et al. (2007). The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1, 84-96.